Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Tofacitinib in patients with severe active Rheumatoid Arthritis

Trial Profile

Efficacy and Safety of Tofacitinib in patients with severe active Rheumatoid Arthritis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary) ; Corticosteroids; Leflunomide; Methotrexate; Prednisone
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Jun 2019 Results (n=26) investigating the effect of tofacitinib on the levels of NT-proBNP during 12-Month Follow-Up, presented at the 20th Annual Congress of the European League Against Rheumatism.
    • 17 Jun 2017 Results (n=28) evaluating the effects of tofacitinib on cardiovascular risk factors in rheumatoid arthritis patients during 12-month follow-up, presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 17 Jun 2017 Pooled results the safety and efficacy of Tofacitinib in patients from this this and one another study (n=142), presented at the 18th Annual Congress of the European League Against Rheumatism
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top